Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway

Bin Wei1,2†, Yuanyuan Wang1†, Jiawei Wang1†, Xiaomin Cai1, Lingyan Xu1, Jingjing Wu2, Ying Wang1, Wen Liu3, Yanhong Gu1*†, Wenjie Guo3* and Qiang Xu3*

Abstract

Background: Esophageal cancer is the sixth leading cause of cancer-related mortality worldwide, which is partially due to limited progress of therapy. Apatinib, an inhibitor of VEGFR2, has a promising antitumor effect on malignancies. However, the underlying mechanism of its antitumor effect on esophageal cancer remains poorly understood.

Materials and methods: Eighteen pairs of frozen esophageal cancer and their para-cancer samples and 25 paraffin specimens from advanced esophageal cancer patients treated with cisplatin-based regimen were collected. The effects of apatinib on cell growth, cell apoptosis, cell cycle and invasion/migration of esophageal cancer cells were assessed. Bioinformatics, luciferase reporter, immunoprecipitation and immunofluorescence assays were conducted for mechanic investigation. Quantitative RT-PCR, western blotting and immunohistochemistry were used to measure the expression of functional genes. Xenograft tumor growth of mice was performed.

Results: We found that VEGFR2 was highly expressed in esophageal cancer and associated with poor efficacy of cisplatin-based treatment. Apatinib displayed profound actions against tumor cell growth of human esophageal cancer via promoting cell apoptosis and cell cycle arrest. Also, apatinib displayed the inhibitory effects on cell migration and invasion. Moreover, apatinib strongly suppressed the growth of esophageal cancer xenografts in mice. The effects of apatinib on esophageal cancer were partially dependent on its block of the VEGFR2/Akt/β-catenin pathway. Specifically, apatinib induced the degradation of β-catenin and decreased its transcriptional activity through Akt/GSK-3β repression. Further in vitro and in vivo studies revealed that low dose apatinib had a synergistic antitumor effect with cisplatin on esophageal cancer.

Conclusion: Our study indicates that apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer by deactivating the Akt/β-catenin pathway. These findings provide a theoretical foundation for using apatinib as an effective therapeutic drug for esophageal cancer.

Keywords: Apatinib, Esophageal cancer, Tumor progression, Cisplatin sensitivity, VEGFR2, Akt/β-catenin pathway

© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
only 15% to 25% [2]. To date, no important progress has been made in the treatment of esophageal cancer, and the main treatments are still surgery, radiotherapy and chemotherapy. Therefore, studies on clinical trials of new drugs that could provide more effective therapy have attracted increasing attention.

Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor that selectively inhibits the VEGFR-2, RET, c-Kit, and c-Src tyrosine kinases [3]. Increasing evidence suggests that apatinib exerts its promising anti-neoplastic activities by inhibiting the cell cycle, inducing apoptosis, suppressing angiogenesis, and inhibiting metastasis of cancer cells in a variety of tumors, such as colon cancer, thyroid cancer, liver cancer, cholangiocarcinoma and osteosarcoma [4–8]. With the tolerable side effects and improved survival benefits, apatinib has been approved by the China Food and Drug Administration for advanced gastric cancer in third-line or later treatment [9]. At present, a series of clinical trials of apatinib have been conducted and achieved improved clinical efficacy in multiple cancers, such as digestive tract cancer, breast cancer and lung cancer [10–15]. Few clinical retrospective studies have preliminarily suggested that apatinib alone or in combination with chemotherapy is efficacious for advanced esophageal cancer as a second-line or later treatment [16, 17]. However, the possible function and mechanism of apatinib in the treatment of esophageal cancer is still poorly understood.

In this study, we found that apatinib inhibited the growth of esophageal cancer and sensitized tumors to cisplatin by deactivating the Akt/β-catenin pathway, which provided a theoretical basis of apatinib as a potential candidate for the treatment of esophageal cancer.

Materials and methods

Patients collection
All patients with histological confirmed esophageal cancer were obtained from The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University (Hua'nan, Jiangsu Province, China). A total of 18 pairs of resected fresh tumor and adjacent nontumor tissues were collected from the patients with stage I–III at the time of surgical resection. For this cohort, the median age was 60 (45–72 years) and 12 cases were male. Also, we obtained 25 advanced or metastatic cases (stage III or IV) treated with first-line cisplatin-based regimen, and their median age was 61 (48–81 years) and 16 cases were male. Treatment outcome was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) system [18]. All patients signed their informed consent. The study protocol was approved by Human Ethics Committee of The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University.

Cell lines
Human esophageal cancer cell lines KYSE30 and TE1 were purchased from Shanghai Cell Bank of Chinese Academy of Sciences (Shanghai, China). Mouse esophageal cancer AKR cell line was purchased from BeNa Culture collection of China (Suzhou, Jiangsu, China) [19]. These cells were cultivated in DMEM high-glucose medium (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA) and cultured in a humidified incubator with 5% CO2 at 37 °C.

Chemicals and antibodies
Apatinib mesylate was donated by Hengrui Medicine Company (Lianyungang, Jiangsu, China). SC79, MG132 and cisplatin were purchased from Selleck Chemicals (Houston, TX, USA). For immunoblotting, the following primary antibodies were used: Bax (catalog no. 5023, 1:1000), Survivin (catalog no. 2808, 1:1000), p21 (catalog no. 2946, 1:1000), Cyclin D1 (catalog no. 2978, 1:1000), E-cadherin (catalog no. 3195, 1:1000), Vimentin (catalog no. 5741, 1:1000), N-cadherin (catalog no. 14215, 1:1000), VEGFR2 (catalog no. 9698, 1:800), p-VEGFR2 (catalog no. 3770, 1:1000), β-catenin (catalog no. 8480, 1:1000 or 1:100), GSK-3β (catalog no. 9832, 1:2000), p-GSK-3β (catalog no. 5558, 1:1000), Lamin B1 (catalog no. 13435, 1:800) (Cell Signaling, Beverly, MA, USA), PCNA (catalog no. 60097-1-lg, 1:500), Akt (catalog no. 10176-2-AP, 1:2000), p-Akt (catalog no. 66444-1-lg, 1:1000) (Proteintech, Wuhan, China), CD31 (catalog no. sc-376764, 1:100), Ub (catalog no. sc-8017, 1:1000) (Santa, Dallas, Texas, USA) and β-Actin (catalog no. P30002, 1:5000), Goat Anti-Mouse IgG-HRP (catalog no. M21001, 1:2000), Goat Anti-Rabbit IgG-HRP (catalog no. M21002, 1:2000) (Abmart, Shanghai, China). Alexa Fluor 488 goat anti-rabbit/mouse IgG (catalog no. A-21222/A-10684, 1:500) was purchased from Thermo Fisher Scientific (MA, USA).

In vitro cytotoxicity
The in vitro cytotoxicity was measured by Cell Counting Kit-8 (CCK-8) (Vicmed, Xuzhou, Jiangsu, China). Cells were plated in 96-well plates and treated with apatinib or cisplatin at indicated concentrations or time. Then, CCK-8 solution was added into each well and incubated at 37 °C for 2 h. The absorbance (450 nm) was measured in microplate reader (Bio-Tek Instruments, USA).

Colony forming assay
Cells were placed into 6-well plates and treated with appropriate drug conditions, with medium replacement every 3–4 days. After 2 weeks, cells were fixed with 4%
paraformaldehyde and stained with 0.1% crystal violet. The colonies were photographed with a digital camera and visible colonies were manually counted.

**Cell apoptotic analysis**
The Annexin V-FITC/PI Apoptosis Detection Kit (KeyGEN, Nanjing, Jiangsu, China) was used to detect apoptotic cells. Cells were collected and mixed with Annexin V-FITC/PI buffer. Flow cytometry (Beckman, Brea, California, USA) was used to identify cells of normal status, early apoptosis, late apoptosis and death. The relative ratio of cells in apoptosis stages was analyzed [20].

**Cell cycle analysis**
The cells were subjected to propidium iodide (PI) staining using the Cell Cycle Detection Kit (KeyGEN, Nanjing, Jiangsu, China) followed by flow cytometry. The levels of cells at different mitotic stages were analyzed by the ModFit program, version 2.0 (Becton–Dickinson, Franklin Lakes, New Jersey, USA) [21].

**Wound healing assay**
Wound healing assay was performed by using a 24-well plate. After cells grew to 90% confluence gently remove the culture, and a linear wound was made by scraping a pipet tip across the confluent cell layer. Cells were washed twice to remove detached cells. The remaining cells were incubated with appropriate apatinib conditions. All wounds were photographed using 200-fold magnification by a light microscope (Olympus, Lake Success, NY, USA). Then, the size of wound was observed and measured at the indicated times.

**Cell invasion assay**
Cell invasion assay was performed using trans-well inserts with Matrigel (BD Biosciences, San Jose, CA, USA). Cells in serum-free medium were re-suspended in upper chambers and treated with apatinib. The cells were allowed to invade at 37 °C for 36 h toward a lower chamber filled with medium containing 20% fetal bovine serum. The cells that passed through the membrane were fixed with 4% paraformaldehyde and stained with 0.1% crystal violet. All specimens were photographed using 200-fold magnification by a light microscope (Olympus, Lake Success, NY, USA). The invaded cells were counted under an inverted microscope in five random fields.

**Quantitative real-time polymerase chain reaction (qPCR)**
Total RNA was extracted with Trizol™ reagent (TaKaRa, Japan) and reverse transcribed with FastQuant RT Kit (Tiangen, Beijing, China) according to manufacturer’s instructions. Then, qPCR analysis was performed using the SYBR Green Kit (Invitrogen, Carlsbad, USA) and quantified by the Real-Time PCR Detection system (Roche, California, USA). Oligonucleotide primers were designed using Primer Bank (http://pga.mgh.harvard.edu/primerbank/index.html). Primer sequences were shown in Additional file 1: Table S1. Each sample was detected in triplicate and relative mRNA levels normalized to the expression of β-Actin were calculated using the 2^{ΔΔCt} method.

**Western blotting**
Whole cells were lysed in RIPA buffer (Beyotime, Shanghai, China) containing protease inhibitor cocktail (Vicmed, Xuzhou, Jiangsu, China) on ice. Equivalent loading protein from different samples was separated by 6–10% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred onto polyvinylidene difluoride (PVDF) membrane (Millipore, MA, USA). Next, the membranes after blocking were incubated with different primary antibodies at 4 °C overnight. Finally, immunoreactive bands after incubation with secondary antibodies conjugated to peroxidase were detected using an ECL kit (Beyotime, Nangjing, Jiangsu, China) according to the manufacturer’s instructions.

**Bioinformatics analysis**
The Kyoto Encyclopedia of Genes and Genomes (KEGG) network database was used to identify the genes enrichment in β-catenin pathway [22]. Then, UALCAN, an interactive web resource for analyzing transcriptome data from The Cancer Genome Atlas (TCGA) database, was employed to verify the expression level of enriched genes in esophageal cancer which were visualized with a heatmap [23].

**TCF-LEF reporter assay**
β-catenin activity was examined using luciferase reporter assay of Cignal Lenti TCF/LEF Reporter (Qiagen, Venlo, Netherlands). After treatment, the reporter activity was quantified and standardized by using the ONE-Glo™ Luciferase Assay System (Promega, Madison, WI, USA) according to manufacturer’s protocol. The luciferase activity was quantified and standardized as described previously [24].

**Isolation of nuclear and cytoplasmic compartments**
The nuclear and cytoplasmic compartment proteins of cells were isolated using a Nuclear and Cytoplasmic Protein Extraction Kit (KeyGEN Biotech, Jiangsu, China) according to the manufacturer’s instruction.

**Immunoprecipitation**
Cells with different treatments were lysed by RIPA buffer and then anti-β-catenin-conjugated Protein A/G agarose
(Santa Cruz, Santa, Dallas, Texas, USA) was used to incubate with cellular extracts at 4 °C overnight. Thereafter, the resultants were washed five times with cold RIPA buffer, boiled in SDS loading buffer, separated by SDS-PAGE followed by immunoblotting.

**Immunofluorescence**

Cells treated with or without apatinib on coverslips were fixed in 4% formaldehyde, permeabilized with 0.5% Triton X-100 (PBS-T) and blocked with 5% BSA. Samples were then stained with anti-β-catenin, CD31 and Fluor-conjugated secondary antibody. The coverslips were counterstained with DAPI and covered with anti-fade reagent (Beyotime, Shanghai, China). Images were captured using 400-fold magnification with a confocal laser scanning microscope (Olympus, Lake Success, NY, USA).

**Animal experiment**

Six- to eight-week-old female C57BL/6 mice were purchased from Model Animal Genetics Research Center of Nanjing University (Nanjing, China). Animal welfare and experimental procedures were carried out strictly following the Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize animals’ suffering and to reduce the number of animals used. AKR cells (2.5 × 10⁶ cells in 100 μl PBS per mouse) were injected into mice by subcutaneous injection [25]. After 10 days, the animals were randomized (n = 5) and gavaged with apatinib (10 and 30 mg/kg/day) or an equal volume of 0.5% carboxymethylcellulose (CMC) as control. Cisplatin (1 mg/kg/day) was intraperitoneally injected with saline as the control. Tumor dimensions were measured using calipers, and tumor volumes were calculated using the following formula: (shortest diameter)² × (longest diameter) × 0.5 [20]. After continuous observation, the tumor tissues were separated from sacrificed mice.

**Histologic analysis, TUNEL assay and immunohistochemistry (IHC)**

TUNEL assay was performed using In Situ Cell Death Detection Kit (Roche, Basel, Switzerland). The immunostaining of PCNA was performed using a Real Envision Detection kit from the Gene Tech Company (Shanghai, China) according to the manufacturer’s instructions. All stained specimens were photographed using 200-fold magnification by a light microscope (Olympus, Lake Success, NY, USA).

**Statistical analysis**

Statistical analyses were performed using the SPSS Statistics software (version 19.0, Chicago, USA). All experimental data were presented as the mean ± standard error of the mean (SEM). One-way ANOVA with Tukey’s correction was used to analyze statistically significant differences between multiple-group comparisons. A two-tailed Student’s t test was used to analyze statistically significant differences between two groups. $P<0.05$ was considered statistically significant.

**Results**

**VEGFR2 expression was higher and correlated with cisplatin-based treatment in esophageal cancer**

To determine the potential role of VEGFR2 in esophageal cancer, we evaluated the VEGFR2 expression in 17 paired cancer and para-cancer tissues. VEGFR2 mRNA and protein expressions were markedly increased in cancer tissues compared with para-carcinoma tissues (Fig. 1a, b). Also, the higher VEGFR2 mRNA expression was associated with a greater TNM stage (Fig. 1c). Additionally, we also explored the relationship between VEGFR2 mRNA expression and chemotherapy sensitivity of cisplatin-based regimen in 25 patients with advanced esophageal cancer. The patients were divided into two groups using median value as the cut-off point, and patients with low VEGFR2 mRNA expression had a high objective response rate (58.3% vs. 15.4%, $P=0.025$; Fig. 1d) compared with those with high expression.

**Apatinib suppressed cell proliferation via inducing cell apoptosis and cell cycle arrest in esophageal cancer**

The cytostatic action of apatinib on esophageal cancer cell lines (KYSE30 and TE1) was assessed by CCK-8 assay. The cell viability of the two cell lines decreased with increasing concentrations and exposure time, indicating that apatinib suppressed cell proliferation in a dose- and time-dependent manner (Fig. 2a). Moreover, a colony formation assay revealed that the number and size of colonies formed by the two tumor cell lines were significantly inhibited by apatinib in a dose-dependent manner (Fig. 2b, c).

Furtherly, flow cytometric analysis of KYSE30 and TE1 cells treated with apatinib showed significant apoptosis induction when compared to that of the control (Fig. 2d, e). Meanwhile, we discovered that apatinib significantly arrested both cell lines at the G0/G1 phase, but fewer cells were in the S phase (Fig. 2f, g). The results from the western blotting assay revealed that apatinib altered the expression of cell cycle- and apoptosis-associated proteins, including upregulation of Bax and p21 and downregulation of Survivin and Cyclin D1 (Fig. 2h). These data indicated that apatinib exerted its antigrowth effect by inducing cell apoptosis and blocking cell cycle progression in esophageal cancer cells.
Apatinib inhibited cell migration and invasion of esophageal cancer

To investigate whether apatinib could inhibit the cellular motility of esophageal cancer, wound healing and transwell assays were conducted. The migration speed of KYSE30 and TE1 cells was significantly decreased following exposure to apatinib relative to that of the control group (Fig. 3a, b). Furthermore, results of another transwell assay showed that apatinib markedly suppressed the invasion ability of these two cell lines (Fig. 3c, d).

Epithelial–mesenchymal transition (EMT) plays a critical role during tumor metastasis, and the expression of markers related to this process was examined by qPCR and western blotting. We found that apatinib treatment resulted in the upregulation of the epithelial marker E-cadherin and the downregulation of mesenchymal markers, including Vimentin and N-cadherin, at both the mRNA and protein levels (Fig. 3e, f). These results suggested that apatinib might reverse the EMT process and control the cell metastasis of esophageal cancer.

Apatinib regulated β-catenin signaling in esophageal cancer

β-Catenin-mediated signaling regulates tumor initiation and progression in multiple malignancies [26]. Here, we analyzed the transcriptome data of esophageal cancer via the UALCAN data portal and found that the majority of genes in the pathway were differentially expressed in tumor tissues compared to normal tissues (Fig. 4a). Then, we investigated whether β-catenin and its downstream effectors were affected by apatinib treatment in the KYSE30 cell line. Decreased expression of β-catenin protein was observed in cells exposed to apatinib, and the expression trend was consistent with the cytoplasm and nucleus (Fig. 4b). To further clarify whether the decrease in β-catenin was mediated by the ubiquitin–proteasome degradation pathway, we used MG132 to inhibit the proteasome and found that ubiquitinated β-catenin was increased in the apatinib-treated group (Fig. 4c).

Furthermore, a luciferase reporter assay discovered that apatinib attenuated β-catenin-mediated transcriptional activity (Fig. 4d). Additionally, the expression levels of several downstream genes of β-catenin were significantly
decreased, including Myc, Jun, Wisp1 and Cyclin D1 (Fig. 4e). In addition, immunofluorescence assay was employed to investigate the location of β-catenin, and the results indicated that treatment with apatinib promoted the transfer of β-catenin from the nucleus to the cytoplasm in esophageal cancer cells (Fig. 4f). Overall, our data demonstrated that the antitumor effects of apatinib occurred through induction of β-catenin degradation.

Apatinib suppressed β-catenin signaling via VEGFR2/Akt/GSK-3β

Recent research has shown VEGFR2 mediates the Akt/GSK3β signaling [4]. Also, the Akt/GSK-3β pathway triggers a network that positively regulates tumor progression by activating β-catenin [27]. We found that the protein expression of p-VEGFR2, p-Akt, p-GSK-3β Ser9 and β-catenin was decreased in KYSE30 cells treated with apatinib (Fig. 5a). To confirm the effect of apatinib on the Akt/β-catenin pathway, cells were pretreated with the Akt agonist SC79 to alter its activity. We demonstrated a decrease in the protein expression of p-Akt and β-catenin (Fig. 5b), the mRNA expression of Myc and Wisp1 (Fig. 5c), and the transcriptional activity of apatinib were restored by SC79 treatment (Fig. 5d). Then, we examined the role of Akt in apatinib-mediated growth inhibition of esophageal cancer. The results showed that the apatinib-mediated proliferation inhibition and apoptosis induction was reversed by SC79 (Fig. 5e, f).
Collectively, these data revealed a possible mechanism by which apatinib inhibited esophageal cancer progression by suppressing the VEGFR2/Akt/GSK-3β/β-catenin pathway.

**Apatinib inhibited tumor growth of esophageal cancer via the VEGFR2/Akt/β-catenin pathway in vivo**

To evaluate the antitumor effect of apatinib in vivo, xenograft mouse models were treated with apatinib by gavage. The growth of tumor xenografts and tumor weights were significantly inhibited by apatinib at a dose of 30 mg/kg (Fig. 6a–c). Also, no mice died during the experiment, and no significantly difference in bodyweight was observed among control and treatment groups (Fig. 6d). The blood vessels in tumors were detected using the CD31 staining, and we found apatinib treatment inhibited angiogenesis of esophageal cancer (Fig. 6e). Furthermore, apatinib inhibited the expression of PCNA (Fig. 6f). In contrast, TUNEL-positive cells were also increased in tumors that received apatinib treatment (Fig. 6g). In this case, dephosphorylation of VEGFR-2 and Akt, β-catenin degradation and decreased levels of Cyclin D1 in tumors were observed after apatinib treatment (Fig. 6i). Furthermore, the mRNA levels of Myc and Jun showed a downward trend (Fig. 6h). Taken together, these in vivo data indicated that apatinib could inhibit xenograft tumor growth in esophageal cancer by blocking the Akt/β-catenin pathway.

**Apatinib sensitized esophageal cancer to cisplatin via the Akt/β-catenin pathway**

To explore whether apatinib could sensitize esophageal cancer to cisplatin, cotreatment with apatinib and cisplatin was performed both in vitro and in vivo. The CCK-8 assay showed that cisplatin-induced growth inhibition was increased in both KYSE30 and TE1 cells cotreated with apatinib (Fig. 7a). Additionally, we discovered the additive effects of two drugs on Akt/β-catenin signaling, and these effects led to lower p-Akt and β-catenin levels than those seen with either treatment alone (Fig. 7b). Furthermore, the in vivo efficacies of low-dose apatinib and/or cisplatin were investigated in the xenograft models. The tumor volumes in mice receiving cotreatment with apatinib and cisplatin were significantly smaller than those in the cisplatin only group (Fig. 7c–e). More importantly, combination of apatinib and cisplatin has no an obvious effect on bodyweight compared with the cisplatin only group (Fig. 7f). Compared with cisplatin alone, TUNEL-positive cells were increased and expressions of p-Akt and β-catenin protein were decreased in tumors after cisplatin and apatinib treatment (Fig. 7g, h). These data indicated that apatinib enhanced the
chemosensitivity of esophageal cancer to cisplatin via suppression of the Akt/β-catenin pathway.

Discussion

Esophageal cancer is a common type of gastrointestinal malignancy with a high mortality rate in China [2, 28]. With the limited progress seen thus far in medical treatment, the prognosis of esophageal cancer has not been significantly improved [29]. Apatinib, as a highly selective tyrosine kinase inhibitor, has exerted promising antitumor effects on malignant tumors [13]. In the present study, our data demonstrated that apatinib inhibited tumor progression and promoted cisplatin sensitivity by negatively regulating the Akt/β-catenin pathway in esophageal cancer (Fig. 7i).

First, we found that VEGFR2 mRNA and protein expression were remarkably increased in esophageal cancer samples compared with associated non-tumor tissues. The finding was in agreement with the results reported in several human cancers [7, 30]. Apatinib, as a highly selective VEGFR2 antagonist, inhibited the growth of human esophageal cancer cells in a time- and dose-dependent manner. Consistent with previous studies in human colon cancer, osteosarcoma and thyroid cancer [4, 7, 8, 33], we also demonstrated that apatinib induced cell apoptosis and cycle arrest at G0/G1 phase in vitro. The results of the xenograft assay further showed that apatinib significantly blocked the tumor growth of esophageal cancer, as well
as inhibited angiogenesis, promoted apoptosis and suppressed the cell cycle in vivo. In addition, our findings suggested that apatinib might inhibit the metastasis of esophageal cancer via EMT inhibition, which was in line with the findings of a study in osteosarcoma [6]. Therefore, we found that apatinib inhibited tumor progression by not only inhibiting angiogenesis but also suppressing tumor cell growth and metastasis.

The Wnt/β-catenin pathway has been implicated in tumorigenesis and progression in many cancer types [34]. Consistent with Deng’s results [35], TCGA data analysis verified that most β-catenin signaling-related genes were differentially expressed in esophageal cancer. Here, we discovered that the level of total or nuclear β-catenin was decreased in response to apatinib treatment. When the upstream pathways are suppressed, β-catenin is phosphorylated and then delivered to the proteasome for degradation [36]. Upon apatinib treatment, an increased level of ubiquitination of β-catenin was observed, which could be degraded by ubiquitination. β-catenin accumulates in the cytoplasm and transfers to the nucleus, where it interacts with TCF/LEF transcription factors, thus affecting a variety of biological processes, including the cell cycle, apoptosis, angiogenesis and metastasis [37, 38]. Consistent with the reduced amount of β-catenin seen in the nucleus, apatinib confined TCF/LEF-mediated transcriptional activity. Accordingly, apatinib blocked β-catenin signaling, which partially explained its antitumor effects.

Recently, studies have suggested that the antitumor function of apatinib may be achieved by regulating VEGFR2-mediated multimodality pathways, such as the RAF/ERK, MAPK, and STAT3/Bcl-2 pathways [5, 33, 39]. Besides, VEGFR2 can positively regulate Akt/GSK-3β signaling [4]. Among Wnt-independent pathways, the Akt can indirectly regulate β-catenin expression by phosphorylating GSK-3β at Ser9 to inactivate its kinase activity [27]. In our study, the degradation of β-catenin, which was mediated by apatinib, was accompanied by a decrease in p-VEGFR2, p-AKT and p-GSK-3β. Further rescue experiments discovered that the decreased expression level and transcriptional activity of β-catenin caused by apatinib were recovered with pretreatment with SC79 (an Akt agonist). Meanwhile, apatinib-mediated cell growth suppression was also reversed by SC79. Similarly, apatinib inhibited the phosphorylation of VEGFR2 or Akt and then increased instability of β-catenin in vivo. Based on our results and the results of others, we speculate that apatinib regulates Akt/β-catenin signaling through its VEGFR2 inactivation, and this mechanism requires further exploration.

Combination strategies that can improve clinical efficacy have become the trend in antitumor therapy, such as chemotherapy combined with targeted therapy or immunotherapy [40]. According to existing research results, VEGFR2 confers to chemoresistance in cancers [41–43]. In our study, we discovered that high VEGFR2 associated with poor clinical efficacy of cisplatin-based
chemotherapy in advanced esophageal cancer. Existing clinical studies have shown that apatinib causes some adverse reactions, such as hypertension, hand and foot syndrome, proteinuria, diarrhea, and the incidence of adverse reactions are increased with the combination of regular dose of apatinib and chemotherapy [17, 44]. Data from a clinical study have demonstrated that low dose apatinib plus chemotherapeutic agent is effective without increasing adverse reactions in lung cancer [45]. Thus, we selected the low dose apatinib to explore its effects on cisplatin sensitivity in esophageal cancer. Here, we discovered that cotreatment with cisplatin and low dose apatinib more effectively inhibited cancer cell proliferation than cisplatin alone in vitro and in vivo. In addition, the combination suppressed the Akt/β-catenin pathway synergistically.
In conclusion, we demonstrated that apatinib inhibited the progression and enhanced the cisplatin sensitivity of esophageal cancer in vivo and in vitro. Moreover, suppression of VEGFR2/Akt/GSK-3β-mediated β-catenin stability and transcriptional activity was implicated in the antitumor effects of apatinib. These findings provide a theoretical foundation for using apatinib as an effective therapeutic strategy for esophageal cancer.

**Conclusion**

In this study, we discovered that apatinib inhibited the growth of esophageal cancer and sensitized tumors to cisplatin by deactivating the Akt/β-catenin pathway, which provided a theoretical basis for apatinib as a potential therapeutic strategy for esophageal cancer.
Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s12935-020-01290-z.

Additional file 1: Table S1. Primers used for qPCR.

Abbreviations

PI: Propidium iodide; qPCR: Quantitative real-time polymerase chain reaction; PAGE: Polyacrylamide gel electrophoresis; P/DV: Polyvinylidene difluoride; KEGG: Kyoto encyclopedia of genes and genomes; TCGA: The cancer genome atlas; IHC: Immunohistochemistry; EMT: Epithelial–mesenchymal transition.

Acknowledgements

The authors thank Dr. Yong Gao of The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University for providing KYSE30 cell line and all patients enrolled in this study.

Authors’ contributions

YHG, WXG and QX conceived and designed the experiments. BW, YYW, JWW, XMC, JWY and YYW performed the experiments. BW, JWW, LYX and WL analyzed the data. BW wrote the paper. All authors read and approved the final manuscript.

Funding

This study was supported by National Natural Science Foundation of China (81871944, 81572389), Jiangsu 333 project (BRA2016517), Jiangsu province Fundamental Research Funds for the Central Universities (020814380114).

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

All patients signed their informed consent. The study protocol was approved by the Human Ethics Committee of The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University. All animal studies were approved by the Institutional Animal Care Committee of Nanjing Medical University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China. 2 Department of Oncology, The Affiliated Huaian No.1 People’s Hospital of Nanjing Medical University, Huaian, China. 3 State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, 22 Hankou Road, Nanjing 210093, China.

Received: 27 January 2020   Accepted: 22 May 2020

Published online: 27 May 2020

References

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505–27.

2. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400–12.

3. Scott AJ, Messersmith WA, Jimeno A. Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today. 2015;51:223–9.

4. Jin Z, Cheng X, Feng H, Kuang J, Yang W, Peng C, et al. Apatinib inhibits angiogenesis via suppressing Akt/GSK3β/PDGα signaling pathway in anaplastic thyroid cancer. Cell Physiol Biochem. 2017;44:1471–84.

5. Huang M, Huang B, Li G, Zeng S. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterol. 2018;18:169.

6. Zheng B, Ren T, Huang Y, Guo W. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. Biochem Biophys Res Commun. 2018;495:1695–701.

7. Wen S, Shao G, Zheng J, Zeng H, Luo J, Gu D. Apatinib regulates the cell proliferation and apoptosis of liver cancer by regulation of VEGFR2/STAT3 signaling. Pathol Res Pract. 2019;215:816–21.

8. Lu W, Ke H, Qianshan D, Zhen W, Guoxan H, Honggang Y. Apatinib has anti-tumor effects and induces autophagy in colon cancer cells. Iran J Basic Med Sci. 2017;20:990–5.

9. Roviello G, Ravelli A, Fiaschi AI, Cappelletti MR, Gobbi A, Senti C, et al. Apatinib for the treatment of gastric cancer. Expert Rev Gastroenterol Hepatol. 2016;10:887–92.

10. Hu J, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, et al. Multicenter phase II study of apatinib, a novel VEGF inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135:1961–9.

11. Song Z, Yu X, Lou G, Shi X, Zhang Y. Salvage treatment with apatinib for advanced non-small-cell lung cancer. Onco Targets Ther. 2017;10:1821–5.

12. Gou M, Shi H, Zhang Y, Qian N, Wang Z, Shi W, et al. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study. Sci Rep. 2018;8:4602.

13. Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137–47.

14. Chen X, Qiu T, Zhu Y, Sun J, Li P, Wang B, et al. A single-arm, phase II study of apatinib in refractory metastatic colorectal cancer. Oncologist. 2019;24:4883.e407.

15. Luo H, Zhang L, Yang B, Peng Y, Xiong Y, Zhang S, et al. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive-stage small cell lung cancer. Invest New Drugs. 2020;38:148–59.

16. Li J, Wang L. Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma. Onco Targets Ther. 2017;10:3965–9.

17. Li J, Jia Y, Gao Y, Zhang Z, Han H, Yan J, et al. Clinical efficacy and survival analysis of apatinib combined with doxetaxel in advanced esophageal cancer. Onco Targets Ther. 2019;12:2577–83.

18. Wei B, Han Q, Xu L, Zhang X, Zhu J, Wan L, et al. Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma. BMC Cancer. 2015;15:331.

19. Ohara T, Takaoka M, Sakurama K, Nagaiishi K, Takeda H, Shirakawa Y, et al. The establishment of a new mouse model with orthotopic esophageal cancer showing the esophageal stricture. Cancer Lett. 2010;293:207–12.

20. Wang W, Guo W, Li L, Fu Z, Liu W, Gao J, et al. Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. Invest New Drugs. 2016;121:8–17.

21. Wang G, Chen H, Huang M, Wang N, Zhang J, Zhang Y, et al. Methyl protodioscin induces G2/M cell cycle arrest and apoptosis in HepG2 liver cancer cells. Cancer Lett. 2006;241:102–9.

22. Kanehisa M, Goto S, Kawashima S, Nakaya A. The KEGG databases at GenomeNet. Nucleic Acids Res. 2002;30:42–6.

23. Chandrashekar DS, Bashel B, Balasubramanya S, Creighton CJ, Ponce-Rodriguez J, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroups gene expression and survival analyses. Neoplasia. 2017;19:649–58.

24. Pai VC, Hsu CC, Chan TS, Liao WY, Chuu CP, Chen WY, et al. ASPM expression regulates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Investig. 2019;130:4850–62.

25. Kumar R, Bashyam MD. Multiple oncogenic roles of nuclear beta-catenin. J Biosci. 2017;42:695–707.
27. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem. 2007;282:11.221–9.

28. Zhang HZ, Jin GF, Shen HB. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer. 2012;31:281–6.

29. Markar SR, Kirthikeshalingam A, Low DE. Outcomes assessment of the management of esophageal cancer in younger and older patients. Ann Thorac Surg. 2012;94:1652–8.

30. Lian L, Li XL, Xu MD, Li WM, Wu MY, Zhang Y, et al. VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer. BMC Cancer. 2019;19:183.

31. Dang YZ, Zhang Y, Li JP, Hu J, Li WW, Li P, et al. High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer. Medicine. 2017;96:e5772.

32. Nasi A, Holzer TR, Chen M, Man MZ, Schade AE. Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies. Cancer Cell Int. 2017;17:56.

33. Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 2017;8:e3015.

34. El-Sahl S, Xie Y, Wang L, Liu S. Wnt signaling in cancer metabolism and immunity. Cancers (Basel). 2019;11:904.

35. Deng F, Zhou K, Cui W, Liu D, Ma Y. Clinicopathological significance of vnt/β-catenin signaling pathway in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8:3045–53.

36. Stamos JL, Weis WI. The β-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013;5:a007898.

37. Kahn M. Can we safely target the WNT pathway. Nat Rev Drug Discov. 2014;13:513–32.

38. Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell. 2017;169:985–99.

39. Deng M, Zha J, Jiang Z, Jia X, Shi Y, Li P, et al. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia. J Transl Med. 2018;16:47.

40. Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019;38:156.

41. Nobrega-Pereira S, Caiado F, Carvalho T, Matias I, Graça G, Gonçalves LG, et al. VEGFR2-mediated reprogramming of mitochondrial metabolism regulates the sensitivity of acute myeloid leukemia to chemotherapy. Cancer Res. 2018;78:731–41.

42. Babyshtkina N, Zavalova M, Tarabanovskaya N, Dronova T, Krakhmal N, Slonimskaya E, et al. Predictive value of vascular endothelial growth factor receptor type 2 in triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Mol Cell Biochem. 2018;444:197–206.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.